INTRODUCTION
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that was initially identified as the intracellular protein that bound the environmental toxicant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), related halogenated aromatics, and polynuclear aromatic hydrocarbons (Nebert et al., 1972; Poland et al., 1976; Gu et al., 2000) . The role of the AhR in mediating the biochemical and toxic responses induced by TCDD and related compounds has been confirmed in AhR knockout (AhR -/-) mice which are resistant to the effects of TCDD (Nebert et al., 1972; Fernandez-Salguero et al., 1995; Schmidt et al., 1996; Mimura et al., 1997) . Ligand-dependent activation of the AhR results in formation of a nuclear complex with the AhR nuclear translocator (Arnt) protein which binds cis-xenobiotic response elements (XREs) in the Cyp1a1 and other target gene promoters (Poland et al., 1976; Hankinson, 1995; Whitlock, 1999) .
However, several non-classical pathways have been discovered and these include AhR interactions with other nuclear partners, binding to non-consensus cis-promoter elements and also responses that are associated with the extranuclear AhR (Blankenship and Matsumura, 1997; Kim et al., 2000; Singh et al., 2007; Vogel et al., 2007; Li and Matsumura, 2008; Dong and Matsumura, 2009; Denison et al., 2011; Jackson et al., 2014; Vogel et al., 2014) .
Since the initial discovery that the AhR binds toxic polychlorinated and polynuclear aromatic hydrocarbons, it has subsequently been shown that the AhR also binds structurally and functionally diverse ligands including health-promoting phytochemicals such indole-3-carbinol, flavonoids and extracts from fruits and vegetables, and a growing list of pharmaceuticals including omeprazole and other 5 DMD #63677
benzimidazoles (Bjeldanes et al., 1991; Denison et al., 1998; Song et al., 2002; Jeuken et al., 2003; Henry et al., 2006; Hu et al., 2007; Safe et al., 2012) . In addition, structurally diverse "endogenous" biochemicals have been identified as AhR ligands, and there is evidence that the tryptophan photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenine may function as endogenous ligands for the AhR (Song et al., 2002; Oberg et al., 2005; Henry et al., 2006; Wincent et al., 2009; Opitz et al., 2011) .
The development of AhR -/-and tissue specific AhR knockout mice has been instrumental in showing that this receptor plays an essential role in various tissues and is a critical regulator of inflammation, autoimmune and immune responses and is a potential drug target for treating multiple diseases including cancer (Kerkvliet, 2009; Stevens et al., 2009; Marshall and Kerkvliet, 2010; Busbee et al., 2013; Safe et al., 2013) . For example, there is extensive evidence that the AhR and its agonists including AhR-active cruciferous vegetables play a protective in mouse models of intestinal cancer and inflammation (Kawajiri et al., 2009; Arsenescu et al., 2011; Benson and Shepherd, 2011; Furumatsu et al., 2011; Kiss et al., 2011; Li et al., 2011; Monteleone et al., 2011; Singh et al., 2011; Lee et al., 2012) .
Several studies have reported that the gut microbiota produces metabolites including AhR-active compounds that could potentially modulate AhR-mediated intestinal resiliency and responses to inflammatory stimuli (Li et al., 2009; Bansal et al., 2010; Zelante et al., 2013; Fukumoto et al., 2014; Venkatesh et al., 2014) . Research in our laboratories has previously investigated the AhR activities of the tryptophan metabolites indole, indole-3-acetate, tryptamine and 3-indoxyl sulfate using CYP1A1
induction as a prototypical AhR-dependent response in human CaCo2 colon cancer 6 DMD #63677 cells (Jin et al., 2014) . In this report, we determined the AhR activity of tryptophan metabolites in a non-transformed young adult mouse coloncyte (YAMC) cell line (D'Abaco et al., 1996) and there were significant differences between YAMC vs CaCo2 cells with respect to the gene-specific AhR agonist and antagonist activities of tryptophan metabolites.
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MATERIAL AND METHODS
Cell Lines, Antibodies, and Reagents. The YAMC cell line was initially generated from the Immorto mouse (Whitehead et al., 1993) and has been previously used in our studies (Kolar et al., 2007; Weige et al., 2009; Turk et al., 2011) . Cells were maintained in RPMI 1640 medium with 5% fetal bovine serum, 5 units/ml mouse interferon- (IF005) (EMD Millipore, Massachusetts), 1% ITS "-" minus (Insulin, Transferrin, Selenium) (41-400-045) (Life Technologies, Grand Island, NY ) at 33C
(permissive conditions). In preparation for experiments, cells were transferred to 37C
(nonpermissive conditions). AhR antibody (BML-SA210) was purchased by Enzo (Enzo Life Sciences Inc., Farmingdale, NY). The MTT assay for metabolic activity of the tryptophan metabolites was determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay essentially as described (Jin et al., 2014) (Supplemental Figure 1) . -ACTIN (A1978) was purchased from Sigma-Aldrich (St. Western Blot Analysis. Cells (1×10 5 ) were plated in six-well plates in RPMI media containing 2.5% FBS for 16 hr and then treated with different concentrations of the compounds for 24 hr. Cells were collected using high-salt buffer (50 mM HEPES, 0.5 mol/l NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 10% glycerol, and 1% Triton-X-100) and 10 l/ml Protease Inhibitor Cocktail (Sigma-Aldrich). Protein lysates were incubated for 5 min at 95C before electrophoresis and then separated on 10% SDS-polyacrylamide gel electrophoresis 120 V for 2 to 3 hr. Proteins were transferred onto polyvinylidene difluoride membranes by wet electroblotting in a buffer containing 25 mM Tris, 192 mM glycine, and 20% methanol for 1.5 hr at 180 mA. Membranes were then blocked for 30 min with specific antibodies. Detection of specific proteins was performed using
Chemiluminescence and then exposed to Kodak image station 4000 mm Pro (Carestream Health, Rochester, NY)
Statistical Analysis. Statistical significance of differences between the treatment groups was determined by an analysis of variance and/or Student's t test, and levels of probability were noted. At least 3 repeated experiments were determined for each data point, and results are expressed as means  SD.
Name Forward Primer Reverse Primer
TBP
GAACAATCCAGACTAGCAGCA GGGAACTTCACATCACAGCTC
Cyp1a1 CTGAAGTGGTTCTGAGCGG TCCACTCCATCTTCCGACTT
Cyp1b1 GGATATCAGCCACGACGAAT ATTATCTGGGCAAAGCAACG
TiParp GCCAGACTGTGTAGTACAGCC GGGTTCCAGTTCCCAATCTTTT Ahrr ACATACGCCGGTAGGAAGAGA GGTCCAGCTCTGTATTGAGGC 10 DMD #63677
RESULTS
YAMC cells were treated with different concentrations of tryptamine (10-100 M),
indole (50-500 M), indole-3-acetate (50-500 M) and indole-3-aldehyde (50-500 M) and induction of Cyp1a1 mRNA was determined (Fig 1A) . Tryptamine and indole-3-acetate significantly induced Cyp1a1 mRNA levels (>10 fold) at concentrations of 50 and 500 M respectively whereas indole and indole-3-aldehyde were inactive. In contrast 0.01-10 nM TCDD, the most potent AhR agonist induced a >600-fold increase in Cyp1a1 mRNA levels with maximal induction by 10 nM TCDD (Fig. 1B) as previously observed in CaCo2 cells (Jin et al., 2014) . Induction of Cyp1a1 mRNA by the tryptophan metabolites ( Fig. 1C) and TCDD was inhibited after cotreatment with the AhR antagonist CH223191 (CH) (Fig. 1D ). In the inhibition experiment we observed some induction of Cyp1a1 by indole and indole-3-aldehyde alone (Fig. 1C ) and over several experiments low level induction responses by these compounds were variable (0-4 fold) but <1% of that observed for TCDD.
Previous studies in CaCo2 cells showed that indole was an AhR antagonist (Jin et al., 2014) and we further investigated the inhibitory effect of the tryptophan metabolites on induction of Cyp1a1 by TCDD ( Fig. 2A) . All four compounds exhibited AhR antagonist activity, and both tryptamine and indole-3-aldehyde decreased induction of Cyp1a1 mRNA by TCDD by >75% which was more effective than observed for CH (Fig. 1D ). Western blot analysis (Fig. 2B) to interpret. We also examined the effects of TCDD, tryptamine and their combination on recruitment of the AhR to the Cyp1a1 XRE in a ChIP assay. After treatment for 2 hr, TCDD alone or in combination with tryptamine induced AhR interactions with the Cyp1a1 promoter, whereas minimal effects were observed in YAMC cells treated with tryptamine alone (Fig. 2C) . These results contrasted to those observed in CaCo2 cells where indole, the most effective AhR antagonist, blocked TCDD-induced AhR interactions with the ICyp1a1 promoter (Jin et al., 2014) . Analysis of these interactions were also investigated after treatment for 24 hr; significant AhR recruitment to the Cyp1a1 promoter was observed after treatment with tryptamine alone and a comparison of the results of 2 and 24 hr treatments suggested that the tryptamine-induced AhR recruitment was a relatively slow process. In contrast, after treatment with TCDD for 24 hr, the AhR binding to the Cyp1a1 promoter was decreased and this was consistent with the observed TCDD-induced degradation of the AhR protein (Fig. 2B) . Despite the inhibition of TCDD-induced Cyp1a1 mRNA levels by tryptamine treatment for 24 hr ( Fig.   2A ), AhR binding to the Cyp1a1 promoter in the combined treatment group was essentially additive (Fig. 2C ). Therefore, it is possible that the inhibition of TCDDinduced Cyp1a1 by tryptamine is post-transcriptional and AhR-independent. YAMC cells were treated with TCDD alone for 24 hr and cotreated with tryptamine after 18, 20, 22
and 23 hr after addition of TCDD. The results showed that there was a time-dependent decrease in induced Cyp1a1 mRNA (Fig. 2D) , suggesting that some of the inhibitory 12 DMD #63677 effects of tryptamine were post-transcriptional and may be due to destabilization of Cyp1a1 mRNA.
The tryptophan metabolites exhibited structure-dependent AhR agonist/antagonist activities with respect to induction of Cyp1a1 in YAMC cells and this pattern of activity was investigated with other Ah-responsive genes (Savas et al., 1994; D'Abaco et al., 1996; Baba et al., 2001; Diani-Moore et al., 2010) . Results in Figure 3A show that TCDD but not indole-3-aldehyde induced Cyp1b1 expression in YAMC cells and in combination studies indole-3-aldehyde partially inhibited TCDD-induced Cyp1b1 expression. Indole was a partial agonist for induction of Cyp1b1 but did not inhibit TCDD-induced Cyp1b1 mRNA levels (Fig. 3B ). Indole-3-acetate ( Fig. 3C ) and tryptamine ( Fig. 3D) induced Cyp1b1 mRNA levels similar to that of TCDD and did not inhibit induction by TCDD, indicating that both compounds were full AhR agonists for induction of Cyp1b1.
A similar approach was used in examine the AhR agonist/antagonist activities of the tryptophan metabolites with respect to regulation of Ahrr and TiParp gene expression. Indole-3-aldehyde minimally induced Ahrr (<2-fold) at the highest concentration (500 M); TCDD induced Ahrr (<7-fold) and in combination indole-3-aldehyde was a weak AhR antagonist (Fig. 4A) . Indole (Fig. 4B ), indole-3-acetate ( Monteleone et al., 2011; Singh et al., 2011) . The severity of the effects of 2,4-trinitrobenzene sulfonic acid-induced colitis (resembles Crohn's disease) in mice was significantly decreased by treatment with the AhR agonists FICZ and TCDD (Benson and Shepherd, 2011) and this was accompanied by suppression of several markers of inflammation. The severity of dextran sodium sulfate-induced colitis in mice was also decreased by the AhR agonists -naphthoflavone (Furumatsu et al., 2011) , TCDD (Benson and Shepherd, 2011) and FICZ , and in the latter study, the AhR antagonist 2-methyl-2H-pyrazole-3-carboxylic acid enhanced the severity of the colitis .
Previously, we investigated the tryptophan metabolites in CaCo2 human colon cancer cells and demonstrated their ligand-dependent AhR agonist and antagonist activities based primarily on modulation of CYP1A1 gene expression (Jin et al., 2014) .
We also observed similar responses in non-transformed YAMC cells where the most active AhR agonists for induction of Cyp1a1 were tryptamine and indole-3-acetate;
however, the fold induction by both compounds was <3% of that observed for TCDD. In contrast, both tryptamine and indole-3-aldehyde were potent inhibitors of TCDD-induced Cyp1a1 in YAMC cells, whereas tryptamine was primarily a full AhR agonist in CaCo2 cells using CYP1A1 mRNA as an endpoint, demonstrating the importance of cell context.
We also investigated the AhR activity of the four tryptophan metabolites using three additional Ah-responsive genes, namely, Ahrr, Cyp1b1 and TiParp, and the results indicated that the AhR agonist and antagonist activities were both compoundand gene-specific (Table 1) . For example, tryptamine was a weak AhR agonist and 16 DMD #63677
partial antagonist for Cyp1a1 mRNA expression; however, examination of the liganddependent recruitment of the AhR complex to the Cyp1a1 promoter (Fig. 2C) did not readily explain a mechanism for the activity of tryptamine as an AhR agonist ( Fig. 2A) .
In a separate experiment, we observed that treatment of YAMC cells with TCDD alone for 24 hr maximally induced Cyp1a1 mRNA which could then be significantly decreased by addition of tryptamine 18, 20 or 22 hr after treatment with TCDD, suggesting that some of the inhibitory effects of tryptamine on induced Cyp1a1 mRNA may be posttranscriptional. In contrast, tryptamine and TCDD induced similar levels of Cyp1b1 mRNA and tryptamine did not affect TCDD-induced Cyp1b1, indicating that tryptamine was a full AhR agonist for this response. The cell context-and gene-specific AhR agonist and antagonist activities of the tryptophan metabolites are not unique and have been observed for other AhR ligands including 6-methyl-1,3,8-trichlorobenzofuran, flavonoids and pharmaceuticals (Astroff et al., 1988; Lu et al., 1996; McDougal et al., 2001; Zhou and Gasiewicz, 2003; Jin et al., 2012; Safe et al., 2012) . We also observed that the AhR antagonist CH inhibited Cyp1a1 induction by TCDD and the tryptophan metabolites, indicating that CH inhibited induction of Cyp1a1 by a diverse spectrum of AhR ligands as previously reported (Choi et al., 2012) . Ongoing studies show that CH also antagonized induction of Cyp1b1 by TCDD and the tryptophan metabolites;
however, CH did not antagonize induction of Ahrr or TiParp by TCDD and tryptophan metabolites (data not shown) and this is currently being investigated.
In summary, our results show that for a limited set of Ah-responsive genes the AhR agonist and antagonist activities of the tryptophan metabolites are gene-specific in non-transformed YAMC cells and different from that previously observed in CaCo2
This article has not been copyedited and formatted. The final version may differ from this version. cancer cells (Jin et al., 2014) . Differences in the AhR agonist and antagonist activities of the tryptophan metabolites are due not only to the transformed vs. non-transformed phenotype of CaCo2 and YAMC cells but also to their different human vs. mouse origins. These results suggest that indole-3-aldehyde, indole, indole-3-acetate and tryptamine are selective AhR modulators (Safe et al., 2013; Murray et al., 2014) 
